alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 23.1** **Consent    of Independent Registered Public Accounting Firm**     We consent to the incorporation by reference in the registration    statements on    Form S-8    (File    No. 33-73044,No. 33-58037,No. 333-33433    and    No. 333-34549)    and in the registration statement on    Form S-4(No. 35-65229)    of our report dated March 31, 2007, on our audit of the    consolidated financial statements of Bell Industries, Inc. as of    December 31, 2006 and for year then ended, which report is    included in the Company’s Annual Report on    Form 10-K    for the year ended December 31, 2006.     /s/ BKD, LLP     Indianapolis, Indiana    March 31, 2007
I 

118TH CONGRESS 

2D SESSION H. R. 7549 

To amend title 38, United States Code, to provide for the termination of 

a certain educational assistance program, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 5, 2024 

Mr. MRVAN introduced the following bill; which was referred to the Committee 

on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to provide for the 

termination of a certain educational assistance program, 

and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Gold Star Family Edu5 cation Parity Act’’. 

6 SEC. 2. TERMINATION OF AUTHORITY FOR CERTAIN EDU7 CATIONAL ASSISTANCE PROGRAM. 

8 (a) SURVIVORS’ AND DEPENDENTS’ EDUCATIONAL

9 ASSISTANCE.—Chapter 35 of title 38, United States Code, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7549 IH

1 is amended by adding at the end the following new sub2 chapter: 

3 ‘‘SUBCHAPTER VIII—TERMINATION 

4 ‘‘§ 3571. Termination of authority 

5 ‘‘(a) IN GENERAL.—The authority to provide edu6 cational assistance under this chapter shall terminate on 

7 August 1, 2028. 

8 ‘‘(b) ELIGIBILITY FOR POST-9/11 EDUCATIONAL AS9 SISTANCE.—An individual who is no longer eligible for 

10 educational assistance under this chapter pursuant to sub11 section (a) shall be entitled to educational assistance 

12 under chapter 33 of this title in the same manner as if 

13 the individual had elected to receive educational assistance 

14 under section 3327 of this title, notwithstanding the re15 strictions on crediting service under section 3322(h)(1) of 

16 this title, but subject to the limitations under section 

17 3327(d)(2) of this title.’’. 

18 (b) CLERICAL AMENDMENT.—The table of sections 

19 at the beginning of such chapter is amended by adding 

20 at the end the following: 

‘‘SUBCHAPTER VIII–TERMINATION

‘‘3571. Termination of authority.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
§ 212.80 What are the requirements associated with labeling and packaging PET drug products? ( a ) A PET drug product must be suitably labeled and packaged to protect the product from alteration, contamination, and damage during the established conditions of shipping, distribution, handling, and use.
( b ) Labels must be legible and applied so as to remain legible and affixed during the established conditions of processing, storage, handling, distribution, and use.
( c ) All information stated on each label must also be contained in each batch production record.
( d ) Labeling and packaging operations must be controlled to prevent labeling and product mix-ups.
### Water resources of the Neuse River Basin, North Carolina

By: G. A. BillingsleyRobert Eugene FishR.G. Schipf

                            https://doi.org/10.3133/wsp1414

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 520.930 Firocoxib paste. ( a ) *Specifications.* Each milligram (mg) of paste contains 0.82 mg firocoxib.
( b ) *Sponsors.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.
( 2 ) *Indications for use.* For the control of pain and inflammation associated with osteoarthritis.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 5788, Feb. 3, 2006, as amended at 84 FR 39183, Aug. 9, 2019]
FORM 10-Q

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

(X)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2007

 

OR

 

( )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from  to ____

 

Commission file number 000-21644

 

**CRIMSON EXPLORATION INC.**

(Exact name of Registrant as specified in its charter)

 

| **Delaware**

(State or other jurisdiction of incorporation)                                                        |   | **20-3037840**

(IRS Employer Identification No.) |
|---------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|
|                                                                                                                |   |                                              |
| **717 Texas Avenue, Suite 2900**

**Houston, Texas**

(Address of principal executive offices)                      |   | **77002**

(zip code)                             |
|                                                                                                                |   |                                              |
| **480 N. Sam Houston Parkway East, Suite 300**

**Houston, Texas**

(Former address of principal executive offices) |   | **77060**

(Former zip code)                      |

 

**(713) 236-7400**

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act.

 

| Large accelerated filer o |   | Accelerated filer o |   | Non-accelerated filer x |
|---------------------------|--------|---------------------|--------|-------------------------|

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

 

On May 11, 2007, there were 4,093,969 shares of common stock outstanding.

 

----
EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(Chief Financial Officer)

In connection with the Quarterly Report of CEC Entertainment, Inc. (the Company) on Form
10-Q for the quarter ended June 29, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned certifies that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|               |  |  |  |                              
|-------------- |  |  |  | -----------------------------
|August 7, 2008 |  |  |  | /s/     Christopher D. Morris
|               |  |  |  | Christopher D. Morris        
|               |  |  |  | Chief Financial Officer
EXHIBIT 32



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350



In connection with the Annual Report on Form 10-KSB for the period ended June 30, 2003 (the Report) of The Southern Banc Company, Inc. (the Company), as filed with the Securities and Exchange Commission on the date
hereof, the undersigned, Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies that to the best of my knowledge:



| | (1) |  | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------------------



| | (2) |  | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered
in the Report.
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Date: September 29, 2003 |  | By:      /s/ Gates Little                                                                  
|------------------------ |  | -------------------------------------------------------------------------------------------
|                         |  | Gates Little                                                                               
|                         |  | President and Chief Executive Officer (Chief Executive Officer and Chief Financial Officer)



A signed original of
the written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The information
furnished herein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.
EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CEC Entertainment, Inc. (the Company) on Form 10-Q for the quarter ended July 2, 2006 as
filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Christopher D. MorrisChristopher D. MorrisChief Financial OfficerApril 23, 2007


A signed original of this written statement required by Section 906 has been provided to CEC
Entertainment, Inc. and will be retained by CEC Entertainment, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



30
§ 582.1736 Sodium bicarbonate. ( a ) *Product.* Sodium bicarbonate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<TABLE> <S> <C>

<ARTICLE>                     5

<S>                                        <C>                    <C>
<PERIOD-TYPE>                                   12-Mos                  6-Mos
<FISCAL-YEAR-END>                          Dec-31-1999            Dec-31-1999
<PERIOD-START>                             Jan-01-1999            Jan-01-2000
<PERIOD-END>                               Dec-31-1999            Jun-30-2000
<CASH>                                         68,000                       0
<SECURITIES>                                         0                      0
<RECEIVABLES>                                        0                      0
<ALLOWANCES>                                         0                      0
<INVENTORY>                                          0                      0
<CURRENT-ASSETS>                               130,000                  9,000
<PP&E>                                         287,000                289,000
<DEPRECIATION>                                 (42,000)               (89,000)
<TOTAL-ASSETS>                               3,406,000              8,310,000
<CURRENT-LIABILITIES>                          972,000              2,627,000
<BONDS>                                              0                      0
<PREFERRED-MANDATORY>                                0                      0
<PREFERRED>                                          0                      0
<COMMON>                                        18,000                 21,000
<OTHER-SE>                                   2,416,000              5,662,000
<TOTAL-LIABILITY-AND-EQUITY>                 3,406,000              8,310,000
<SALES>                                              0                      0
<TOTAL-REVENUES>                                     0                      0
<CGS>                                                0                      0
<TOTAL-COSTS>                                        0                      0
<OTHER-EXPENSES>                            (5,652,000)           (10,306,000)
<LOSS-PROVISION>                                     0                      0
<INTEREST-EXPENSE>                             (34,000)              (144,000)
<INCOME-PRETAX>                             (5,686,000)           (10,450,000)
<INCOME-TAX>                                         0                      0
<INCOME-CONTINUING>                         (5,686,000)           (10,450,000)
<DISCONTINUED>                                       0                      0
<EXTRAORDINARY>                                      0                      0
<CHANGES>                                            0                      0
<NET-INCOME>                                (5,686,000)           (10,450,000)
<EPS-BASIC>                                      (3.98)                 (5.29)
<EPS-DILUTED>                                    (3.98)                 (5.29)



</TABLE>
§ 582.1428 Magnesium hydroxide. ( a ) *Product.* Magnesium hydroxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.7351 Gum tragacanth. ( a ) *Product.* Tragacanth (gum tragacanth).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Exhibit 11

                            RMED International, Inc.
                                   Exhibit 11

The following  represents the  computation of earnings per share  reflecting the
assumption that the granted shares under the option plan which would be dilutive
will be exercised.

                                                         Three Months Ended
                                                    ----------------------------
                                                     March 31,        March 31,
                                                       2000              1999
                                                    ----------------------------

Net income                                          $   107,746      $   262,457
                                                    ===========      ===========

Weighted average common
  shares outstanding                                  9,983,584        9,205,680

Common share equivalents relating
  to stock options                                        3,968        1,306,202
                                                    -----------      -----------

Adjusted common and common equivalent
  shares for computation                              9,987,552       10,511,882
                                                    ===========      ===========

Net earnings per share:
  Basic                                             $      0.01      $      0.03
                                                    ===========      ===========
  Diluted                                           $      0.01      $      0.02
                                                    ===========      ===========

The accompanying notes are an integral part of these statements.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                       3,329,964
<SECURITIES>                                         0
<RECEIVABLES>                                1,698,358
<ALLOWANCES>                                    10,000
<INVENTORY>                                  2,525,934
<CURRENT-ASSETS>                             8,378,487
<PP&E>                                      89,660,508
<DEPRECIATION>                              10,038,778
<TOTAL-ASSETS>                              89,358,397<F1>
<CURRENT-LIABILITIES>                        6,252,600
<BONDS>                                      7,762,500
<PREFERRED-MANDATORY>                       16,021,755
<PREFERRED>                                          0
<COMMON>                                        38,438
<OTHER-SE>                                  57,019,617
<TOTAL-LIABILITY-AND-EQUITY>                89,358,397
<SALES>                                      6,972,249<F2>
<TOTAL-REVENUES>                             6,972,249<F2>
<CGS>                                        5,100,069
<TOTAL-COSTS>                                7,272,488
<OTHER-EXPENSES>                              (35,745)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             130,418
<INCOME-PRETAX>                              (394,912)
<INCOME-TAX>                                 (138,220)
<INCOME-CONTINUING>                          (256,692)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (256,692)
<EPS-PRIMARY>                                   (0.03)
<EPS-DILUTED>                                   (0.03)
<FN>
<F1>Total Assets includes Assets Held for Sale of $721,963.
<F2>Sales and Total Revenues are net of federal and state excise taxes.
</FN>
        

</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               OCT-01-2000
<CASH>                                          16,097
<SECURITIES>                                         0
<RECEIVABLES>                                    6,043
<ALLOWANCES>                                        22
<INVENTORY>                                      8,875
<CURRENT-ASSETS>                                41,942
<PP&E>                                         460,149
<DEPRECIATION>                                 140,472
<TOTAL-ASSETS>                                 373,596
<CURRENT-LIABILITIES>                           44,563
<BONDS>                                         49,354
<PREFERRED-MANDATORY>                            2,411
<PREFERRED>                                          0
<COMMON>                                         3,415
<OTHER-SE>                                     263,605
<TOTAL-LIABILITY-AND-EQUITY>                   373,596
<SALES>                                        387,995
<TOTAL-REVENUES>                               390,681
<CGS>                                          172,760
<TOTAL-COSTS>                                  315,353
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,473
<INCOME-PRETAX>                                 75,328
<INCOME-TAX>                                    29,226
<INCOME-CONTINUING>                             46,102
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    46,102
<EPS-BASIC>                                       1.71
<EPS-DILUTED>                                     1.66


</TABLE>
§ 556.226 Enrofloxacin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of enrofloxacin is 3 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for enrofloxacin are: ( 1 ) *Cattle.* Liver (target tissue): 0.1 ppm desethylene ciprofloxacin (marker residue).
( 2 ) *Swine.* Liver (target tissue): 0.5 ppm enrofloxacin (marker residue).
( c ) *Related conditions of use.* See §§ 516.812 and 522.812 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]